Literature DB >> 26720836

Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab.

Pascal M Lavoie1, Alfonso Solimano2, Richard Taylor3, Eddie Kwan4, Jennifer Claydon5, Stuart E Turvey6, Nico Marr7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26720836      PMCID： PMC5647159          DOI： 10.1001/jamapediatrics.2015.3235

Source DB:  PubMed          Journal:  JAMA Pediatr        ISSN： 2168-6203            Impact factor:   16.193


× No keyword cloud information.
  6 in total

1.  Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus.

Authors:  Daniel M Weinberger; Joshua L Warren; Claudia A Steiner; Vivek Charu; Cécile Viboud; Virginia E Pitzer
Journal:  Clin Infect Dis       Date:  2015-04-22       Impact factor: 9.079

2.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

Authors:  S Johnson; C Oliver; G A Prince; V G Hemming; D S Pfarr; S C Wang; M Dormitzer; J O'Grady; S Koenig; J K Tamura; R Woods; G Bansal; D Couchenour; E Tsao; W C Hall; J F Young
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

3.  CARESS: the Canadian registry of palivizumab.

Authors:  Ian Mitchell; Bosco A Paes; Abby Li; Krista L Lanctôt
Journal:  Pediatr Infect Dis J       Date:  2011-08       Impact factor: 2.129

4.  Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.

Authors:  Alexander Gutfraind; Alison P Galvani; Lauren Ancel Meyers
Journal:  JAMA Pediatr       Date:  2015-04       Impact factor: 16.193

5.  Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.

Authors: 
Journal:  Pediatrics       Date:  2014-08       Impact factor: 7.124

6.  Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus.

Authors:  Vivian Luchsinger; Pedro A Piedra; Mauricio Ruiz; Enna Zunino; María Angélica Martínez; Clarisse Machado; Rodrigo Fasce; María Teresa Ulloa; Maria Cristina Fink; Pamela Lara; Luis F Avendaño
Journal:  Clin Infect Dis       Date:  2012-01-11       Impact factor: 9.079
  6 in total
  5 in total

1.  Letters to the Editor.

Authors:  Karen Chang; Dennis Gurwitz; Peter Azzopardi; Shaheen Doctor; Ronik Kanani; Constantine Petrou; Paul Meinert; Meera Umamaheswaran Kissoon
Journal:  Paediatr Child Health       Date:  2016 Jun-Jul       Impact factor: 2.253

Review 2.  Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.

Authors:  Bernhard Resch
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

3.  Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design.

Authors:  Stephanie E Reuter; Allan M Evans; Michael B Ward
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-12-05

4.  Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus.

Authors:  Anna Bootz; Astrid Karbach; Johannes Spindler; Barbara Kropff; Nina Reuter; Heinrich Sticht; Thomas H Winkler; William J Britt; Michael Mach
Journal:  PLoS Pathog       Date:  2017-08-30       Impact factor: 6.823

5.  Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.

Authors:  Jennifer Claydon; Amitava Sur; Allison Callejas; Mihoko Ladd; Eddie Kwan; Richard Taylor; Stuart E Turvey; Alfonso Solimano; Pascal M Lavoie; Nico Marr
Journal:  PLoS One       Date:  2017-04-24       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.